文献速递肝病消化道肿瘤与早癌

美国与日本监测发现的肝细胞癌结局比较

Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-10-22

该研究比较了2006至2015年间美国和日本四个中心监测发现的肝细胞癌患者的特征与预后。在3788例患者中,1797例(47.4%)为监测发现,美国患者肝功能更差且肿瘤负荷更大。多因素分析显示美国监测发现患者生存更差(HR 1.17,95%CI 1.00-1.35),但调整治疗类型后差异不再显著。

要点

  • 美国监测发现的肝细胞癌患者肝功能更差、肿瘤负荷更大。
  • 美国患者生存显著差于日本(HR 1.17,95%CI 1.00-1.35)。
  • 调整治疗类型后生存差异不再显著,提示治疗差异是主因。

核心结论

  • 美国监测发现的肝细胞癌患者预后差于日本,主要由治疗实施差异驱动。

研究设计与样本

  • 共3788例肝细胞癌患者,其中1797例(47.4%)为监测发现,美国715例,日本1082例。

主要发现

  • 美国监测发现患者肝功能更差且肿瘤负荷更大。
  • 多因素分析显示美国患者生存显著更差(HR 1.17,95%CI 1.00-1.35),倾向性评分匹配分析结果一致。
  • 调整治疗类型后生存差异不再显著(HR 1.07,95%CI 0.92-1.25)。
  • 按治疗类型分层,除美国接受切除的患者生存低于日本外,两国生存可比。

临床怎么用

  • 应关注监测发现肝细胞癌后的治疗实施差异,以改善美国患者预后。

局限性

  • 需进一步研究阐明导致治疗差异的原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Differences in outcomes of hepatocellular carcinoma (HCC) between countries have been largely attributed to variation in the conduct of surveillance and subsequent HCC treatment eligibility. However, differences in outcomes among those detected under surveillance have not been well described. We compared characteristics and prognosis between patients with surveillance-detected HCC from the United States (US) and Japan. METHODS: Patients in whom initial HCC was detected under surveillance between January 2006 and December 2015 from two centers in the US and two from Japan were included. Survival was compared between patients from the US and Japan using multivariable Cox regression analysis and propensity-score matched analysis. We performed subgroup analyses by liver disease etiology, tumor stage, and type of HCC treatment. RESULTS: Of 3788 HCC patients, 1797 (47.4%) were diagnosed under surveillance, 715 from the US and 1082 from Japan. Patients from the US diagnosed under surveillance had worse liver dysfunction and larger tumor burden than those from Japan. In multivariate analysis, US patients with surveillance-detected HCC had significantly worse survival than those from Japan (HR 1.17, 95% CI 1.00-1.35), which was also observed in propensity-score matched analysis. However, this difference was no longer significant after adjusting for treatment type (HR 1.07, 95% CI 0.92-1.25). When stratified by treatment type, survival was comparable between the two countries except lower survival among patients who underwent resection in the US versus Japan. CONCLUSIONS: Prognosis of patients with surveillance-detected HCC is poorer in the US than Japan, primarily driven by differences in treatment delivery. Studies are necessary to elucidate reasons for these differences.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Toyoda H, Hiraoka A, Olivares J, et al. Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. Clin Gastroenterol Hepatol. 2020. PMID: 33295281. doi:10.1016/j.cgh.2020.10.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。